Crossmark

The age of enlightenment in melanoma immunotherapy

Crossref DOI link: https://doi.org/10.1186/s40425-018-0397-8

Published Online: 2018-08-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Albertini, Mark R. https://orcid.org/0000-0002-6499-517X
License Information

Text and Data Mining valid from 2018-08-22
More Information

Article History

Received: 10 May 2018

Accepted: 14 August 2018

First Online: 22 August 2018

Author’s information

: MRA is Associate Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, Director of the Melanoma Disease Oriented Team (DOT) at the University of Wisconsin Carbone Cancer Center (UWCCC), and Chief of Oncology at the William S. Middleton Memorial Veterans Hospital.

: Not applicable

: Not applicable

: The author has research collaborations through the University of Wisconsin with Bristol Myers Squibb (Redwood City, CA and Princeton, NJ) and with Apeiron Biologics (Vienna, Austria). The author declares no competing interests related to this publication.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.